Rae S A, Williams I A, English J, Baylis E M
Br J Clin Pharmacol. 1982 Sep;14(3):459-61. doi: 10.1111/j.1365-2125.1982.tb02010.x.
Eleven patients with stable rheumatoid disease (RD) who were receiving regular corticosteroid therapy (CS) were investigated to discover the effect on plasma prednisolone levels of additional therapy with the non-steroidal anti-inflammatory (NSAI) drugs, indomethacin and naproxen. There was a highly significant (P less than 0.001) increase in free prednisolone levels after concurrent therapy with either indomethacin or naproxen for 2 weeks. Total prednisolone levels were unchanged. These results could provide an explanation for clinical reports that these two NSAI drugs possess a steroid-sparing effect.
对11名正在接受常规皮质类固醇治疗(CS)的稳定型类风湿病(RD)患者进行了研究,以探讨非甾体抗炎药(NSAI)吲哚美辛和萘普生的附加治疗对血浆泼尼松龙水平的影响。在同时使用吲哚美辛或萘普生治疗2周后,游离泼尼松龙水平有极显著升高(P<0.001)。泼尼松龙总水平未变。这些结果可以解释关于这两种NSAI药物具有激素节省效应的临床报告。